Leerink raised the firm’s price target on Guardant Health (GH) to $155 from $115 and keeps an Outperform rating on the shares. After crushing numbers in Q3, the firm is updating its analysis to account for the sustained and growing momentum across Guardant’s portfolio. Leerink sees 20%-plus revenue upside vs consensus in 2026 and 60%-plus upside to Guardant’s current stock price in the bull case scenario.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health: Strong Growth Potential and Market Positioning Justify Buy Rating
- Guardant Health price target raised to $120 from $90 at JPMorgan
- Guardant Health price target raised to $120 from $93 at Wells Fargo
- Guardant Health price target raised to $120 from $85 at Barclays
- GeneDx price target raised to $200, named 2026 Top Pick at BTIG